BFC Planning, Inc.’s Monte Rosa Therapeutics GLUE Stock Holding History

BFC Planning, Inc.’s Portfolio GLUE Stock Details GLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$387	Buy	+16	New	+$302	﹤0.01%	3276

Other funds holding GLUE

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BFC Planning, Inc.'s GLUE Position: Q2 2026 in Review

BFC Planning, Inc. opened a new position in Monte Rosa Therapeutics (GLUE) in Q2 2026: 16 shares worth $387. The stake represents ﹤0.01% of the portfolio and ranks #3276 among its holdings.

194 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

BFC Planning, Inc. held 16 shares of Monte Rosa Therapeutics worth $387 as of Q2 2026.
Monte Rosa Therapeutics was a new BFC Planning, Inc. position in Q2 2026.
Monte Rosa Therapeutics made up ﹤0.01% of BFC Planning, Inc.'s portfolio in Q2 2026, its #3276 holding.
194 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on BFC Planning, Inc.'s 13F filing for Q2 2026, filed 29 Oct 2026.